1. DATE ISSUED M	M/DD/YYYY 1	YY 1a. SUPERSEDES AWARD NOTICE dated 06/21/2020						
09/23/2020		except that any additions or restrictions previously imposed remain in effect unless specifically rescinded						
2. CFDA NO. 93 268 - Immunizati	ion Cooperative A	greements						
3. ASSISTANCE TYPE Cooperative Agreement								
4. GRANT NO. 6 NH2	23 P922606-02-01	1	5. TYPE OF AWARD					
Formerly			Demonstration					
4a. FAIN NH23IP922	606		5a. ACTION TYPE	Post Award Amendment				
6. PROJECT PERIOR) MM/DD/\	YYYY		MM/DD/YYYY				
From	07/01/20	19	Through	06/30/2024				
7. BUDGET PERIOD	MM/DD/\	YYYY		MM/DD/YYYY				
From	07/01/20	20	Through	06/30/2021				

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

CDC Office of Financial Resources

2939 Brandywine Road Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b. 247b(k)(2) and 247c). as amended.

8. TITLE OF PROJECT (OR PROGRAM)

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

A COLUMN AND ADDRESS			at opasi	EE DDG JEGT DIDECTOR			
9a. GRANTEE NAME AND ADDRESS				EE PROJECT DIRECTOR			
HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF			Ms. Jennifer VanBooven 920 Wildwood Dr				
920 Wildwood Dr							
Jefferson City, MO 65109-5796				unity and Public Health			
				on City, MO 65109-5796 : 573-526-6643			
40- CDANTEE AUTHODIZING OFFIC	NAI						
10a. GRANTEE AUTHORIZING OFFIC	JAL			AL PROJECT OFFICER			
Ms. Marcia Mahaney				nan Awwad Clifton Rd NE			
920 Wildwood Dr				ization Services Division (ISD)			
Jefferson City, MO 65109-5796				i, GA 30329-4018			
Phone: 573-751-6014				: 404.718.4623			
44 ADDDOVED BURGET (F. J. J. B.		AMOUNTS ARE					
11. APPROVED BUDGET (Excludes Di	·			COMPUTATION	itom 11m)		9,251,474 00
I Financial Assistance from the Federa			1	f Federal Financial Assistance (from	•		307,400 00
II Total project costs including grant fun	ids and all other financial participation			bligated Balance From Prior Budget			•
a. Salaries and WageS		1,858,153.00) · · · · · · · · · · · · · · · · · ·			5,613,053 00	
b. Fringe Benefits		1,101,391.00)			3,331,021 00	
c. Total Personnel Costs		2,959,544.00				16,946,125.00	
		0.00		ne availability of funds and satisfactor	ry progress of the	project):	
d. Equipment			YEAR	TOTAL D RECT COSTS	YEAR	ТОТА	L D RECT COSTS
e. Supplies		1,263,934.00	a. 3	TOTAL DIRECT COSTS	d. 6	TOTAL	_ D RECT COSTS
f. Travel		458,585.00	b. 4		e. 7		
g. Construction		0.00	c. 5		f. 8		
h. Other		1,263,428.00		INCOME SHALL BE USED IN ACCORD WITH	ONE OF THE FOLLOW	/ING	
i. Contractual		2,672,919.00	ALTERNATIVE: a.	DEDUCTION			
		8.618.410.00	b. c.	ADDITIONAL COSTS MATCHING			b
j. TOTAL D RECT COSTS		0,010,410.00	d. e.	OTHER RESEARCH (Add / Deduct Option) OTHER (See REMARKS)			
k. NDIRECT COSTS		633,064.00	16. THIS AWAR	D IS BASED ON AN APPLICATION SUBMITTE	D TO, AND AS APPRO	OVED BY. THE FE	EDERAL AWARDING AGENCY
			ON THE ABOVE	TITLED PROJECT AND IS SUBJECT TO THE TI NCE IN THE FOLLOWING:	ERMS AND CONDITION	NS INCORPORAT	ED EITHER DIRECTLY
I. TOTAL APPROVED BUDGE	Т	9,251,474.00	a.	The grant program legislation			
			b. c.	The grant program regulations. This award notice including terms and conditions	s, if any, noted below un	nder REMARKS.	
m. Federal Share		9,251,474.00		Federal administrative requirements, cost princip	ples and audit requirem	ents applicable to	-
n. Non-Federal Share		0.00	prevail. Accept	re are conflicting or otherwise inconsistent p ance of the grant terms and conditions is ac he grant payment system.			
REMARKS (Other Terms and C	onditions Attached - X Yes	Г	No)				
,	comments shown in the Grant Notes titled "	■ OGS Budget Review		nd the technical review from Program	n within 30 days o	of the issue da	ate shown on this Notice
of award. Please upload the resp					50 00,00		

GRANTS MANAGEMENT OFFICIAL

Brownie Anderson-Rana, Grants Management Officer 2939 Flowers Road

Mailstop TV2 Atlanta, GA 30341-5509 Phone: 770-488-2771

17.0BJ C	CLASS 41 51	18a. VENDOR CODE		18b. EIN		19. DUNS	878092600	20. CON	G. DIST.	03
	FY-ACCOUNT NO.	DOC	UMENT NO.	Α	DMINISTRATIVE CODE	AMT	ACTION FIN ASST	APP	PROPRIATI	ON
21. a.	0-9390BKG	b. 19N	H23IP922606	C.	IP	d.	\$85,079.00	e.	75-75-X-0	512-009
22. a.	0-9390FG3	b. 20NH	23IP922606C3	C.	IP	d.	\$3,245,942.00	e.	75-20	24-0943
23. a.		b.		C.		d.		e.		

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3		DATE ISSUED 09/23/2020
GRANT NO.	6 NH	23IP922606-02-01

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3		DATE ISSUED 09/23/2020
GRANT NO.	6 NH	23IP922606-02-01

Federal Financial Report Cycle						
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date			
07/01/2019	06/30/2020	Annual	09/28/2020			
07/01/2020	06/30/2021	Annual	09/28/2021			

AWARD ATTACHMENTS

Missouri Department of Health

6 NH23IP922606-02-01

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount **\$3,331,021** is approved for the Year 02 budget period, which is July1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
CORE	\$85,079
COVID-19 CARES	\$3,245,942

Recipients have until July 5, 2021 to expend all COVID-19 funds awarded herein

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS—CoV—2 or to diagnose a possible case of COVID—19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-

reporting-guidance.pdf.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients: https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 and VFC Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification and workplan within 30 days after the receipt of this Notice of Award. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date. A separate narrative and workplan must be submitted in accordance with the COVID-19 guidance and must also be uploaded in GMM as an amendment with a SF424A.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services Wayne Woods, Grants Management Officer Centers for Disease Control and Prevention Branch 1 2939 Flowers Road, M/S E-15 Atlanta. GA 30341

Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services Office of the Inspector General ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue, SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line)

or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Component: CORE

Document Number: 19NH23IP922606

Component: COVID-19

Document Number: 20NH23IP922606C3

CDC Staff Contacts

Grants Management Specialist:

Wayne Woods, Grants Management Specialist (GMS) Centers for Disease Control and Prevention Branch 1 2920 Brandywine Road, M/S E-15 Atlanta, GA 30341

Telephone: 770-488-2948 Email: kuv1@cdc.gov

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.